Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.70 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | DPYD | Q12882 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymine SCHEMBL17144680 | 0.88 | ATAD2 (0.54) | ATAD2CRBNMMP2DPYDALDH1A1 | |
| Thymine SCHEMBL3657360 | 0.84 | ATAD2 (0.50) | ATAD2CRBNMMP2LMNAHTT | |
| Thymine SCHEMBL750450 | 0.84 | ATAD2 (1.00) | ATAD2DPYDALDH1A1GAALMNA | |
| Thymine SCHEMBL5235 | 0.84 | — | — | |
| Thymine SCHEMBL29669526 | 0.84 | — | — | |
| Thymine SCHEMBL17201833 | 0.84 | ATAD2 (1.00) | ATAD2DPYDALDH1A1GAALMNA | |
| Thymine SCHEMBL15323914 | 0.84 | ATAD2 (1.00) | ATAD2DPYDALDH1A1GAALMNA | |
| Thymine SCHEMBL5007601 | 0.84 | ATAD2 (0.68) | ATAD2CRBNMMP2DPYDALDH1A1 | |
| Thymine SCHEMBL23388801 | 0.82 | ATAD2 (0.95) | ATAD2DPYDALDH1A1GAALMNA | |
| Thymine SCHEMBL2724033 | 0.82 | ATAD2 (0.95) | ATAD2DPYDALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728092-A1 | DETERMINATION OF MODIFIED CYTOSINES | Illumina, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4494151-A1 | METHODS OF DETERMINING SEQUENCE INFORMATION | Illumina, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2024256581-A1 | DETERMINATION OF MODIFIED CYTOSINES | ILLUMINA, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| US-20240352515-A1 | METHODS OF BASE CALLING NUCLEOBASES | ILLUMINA INC (US) | 2024-10-24 | — | — | US | claimed |
| US-20240301464-A1 | CONCURRENT SEQUENCING OF FORWARD AND REVERSE COMPLEMENT STRANDS ON SEPARATE POLYNUCLEOTIDES FOR METHYLATION DETECTION | ILLUMINA INC (US) | 2024-09-12 | — | — | US | claimed |
| US-20240287578-A1 | CONCURRENT SEQUENCING OF FORWARD AND REVERSE COMPLEMENT STRANDS ON CONCATENATED POLYNUCLEOTIDES FOR METHYLATION DETECTION | ILLUMINA, INC. | 2024-08-29 | — | — | US | claimed |
| CN-118086471-A | Methods, compositions, systems, instruments and kits for nucleic acid amplification | 生命技术公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4341426-A2 | CONCURRENT SEQUENCING OF FORWARD AND REVERSE COMPLEMENT STRANDS ON SEPARATE POLYNUCLEOTIDES FOR METHYLATION DETECTION | Illumina, Inc. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4341435-A1 | METHODS OF BASE CALLING NUCLEOBASES | Illumina, Inc. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4341425-A2 | CONCURRENT SEQUENCING OF FORWARD AND REVERSE COMPLEMENT STRANDS ON CONCATENATED POLYNUCLEOTIDES FOR METHYLATION DETECTION | Illumina, Inc. (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2023175037-A2 | CONCURRENT SEQUENCING OF FORWARD AND REVERSE COMPLEMENT STRANDS ON SEPARATE POLYNUCLEOTIDES FOR METHYLATION DETECTION | ILLUMINA, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-1399108-A2 | PREPARATION OF A THERAPEUTIC COMPOSITION | Advanced Viral Research Corp. (US) | 2004-03-24 | — | — | EP | claimed |
| US-20030158107-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2003-08-21 | — | — | US | claimed |
| US-20030134782-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2003-07-17 | — | — | US | claimed |
| EP-0679657-B1 | Nucleosides and oligonucleotides containing 2'-ether groups | NOVARTIS AG (CH) | 2003-07-09 | — | — | EP | claimed |
| US-6528098-B2 | Viricides | ADVANCED VIRAL RESEARCH CORP. | 2003-03-04 | — | — | US | claimed |
| WO-2002056833-A2 | PREPARATION OF A THERAPEUTIC COMPOSITION | ADVANCED VIRAL RESEARCH CORP. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20020004579-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2002-01-10 | — | — | US | claimed |
| EP-0040099-A1 | Polynucleotide synthesis | ens BIO LOGICALS INC. (CA) | 1981-11-18 | — | — | EP | claimed |
| US-4205134-A | Carrier for liquid chromatography | TOYO SODA MANUFACTURING COMPANY, LTD. (JP) | 1980-05-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158107-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | ATAD2 4464/4885CRBN 4104/4885MMP2 3527/4885 |
| US-20020004579-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | ATAD2 4464/4885CRBN 4104/4885MMP2 3527/4885 |
| US-20030134782-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | ATAD2 4464/4885CRBN 4104/4885MMP2 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.